Mesoblast (ASX:MSB) Announces U.S. Tariff Exemption for Allogeneic Cell Therapies
Tariff Exemption Granted
Mesoblast announced that its allogeneic cell therapy products, including Ryoncil® and Revascor®, are designated as ‘U.S. Country of Origin’ and are not subject to U.S. tariffs.
Product Portfolio and Development
The company’s Ryoncil® (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients. Mesoblast utilises proprietary remestemcel-L and rexlemestrocel-L platforms to develop off-the-shelf cellular medicines, manufactured from U.S. donors in the U.S. Additionally, Mesoblast is advancing Ryoncil® for adult SR-aGvHD and other inflammatory conditions, while rexlemestrocel-L is being developed for heart failure and chronic low back pain. The company has commercial partnerships in Japan, Europe, and China.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
